BUSINESS

Pfizer Wringing Hands over PMP Eligibility for Lorlatinib; It Might Earn 1st Conditional OK, but It’s “4th” ALK Inhibitor

July 5, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Will Pfizer Japan’s next-generation ALK inhibitor lorlatinib qualify for the price maintenance premium (PMP) scheme for innovative medicines? The drug might bag the country’s first conditional drug approval as early as this autumn, but its fourth-in-class status in the ALK…

To read the full story

Despite Being 4th in ALK Class, Lorbrena Qualifies for PMP as It Gets 5% Pricing Premium
November 14, 2018
Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018

BUSINESS

RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
Chugai to Launch US Partnering Office in January 2026
December 15, 2025
Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…